Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Leases: 2022-2025

Historic Operating Leases for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Sep 2025 value amounting to $2.1 million.

  • Phathom Pharmaceuticals' Operating Leases was N/A to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $462,000 for FY2023, which is 57.92% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Operating Leases of $2.1 million as of Q3 2025, which was up 260.44% from $589,000 recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Operating Leases peaked at $2.1 million during Q3 2025, and registered a low of $133,000 during Q2 2024.
  • In the last 3 years, Phathom Pharmaceuticals' Operating Leases had a median value of $608,500 in 2023 and averaged $745,125.
  • Per our database at Business Quant, Phathom Pharmaceuticals' Operating Leases crashed by 83.14% in 2024 and then skyrocketed by 342.86% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Operating Leases (Quarterly) stood at $1.1 million in 2022, then crashed by 57.92% to $462,000 in 2023, then tumbled by 83.14% to $133,000 in 2024, then spiked by 342.86% to $2.1 million in 2025.
  • Its Operating Leases stands at $2.1 million for Q3 2025, versus $589,000 for Q2 2025 and $133,000 for Q2 2024.